The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Public health impact of antiviral therapy for hepatitis C in the United States†
Open accessAbstract
UNLABELLED: Despite dramatic improvements in antiviral therapy for hepatitis C, there is reason to believe that the uptake of antiviral therapy remains limited. The aims of this study were to determine the number of patients being treated with antiviral therapy in the U.S., to estimate the public health impact of these treatment patterns, and to identify barriers to treatment for patients with hepatitis C. Data on the number of new patient pegylated interferon prescriptions each year, from 2002-2007, was obtained from Wolters Kluwer Inc., which maintains an electronic audit of pharmacies nationwide. A Markov model was created of the population with chronic hepatitis C in the U.S. from 2002 to 2030, and was used to estimate the number of liver-related deaths caused by hepatitis C that will be prevented by current treatment patterns. The National Health and Nutrition Evaluation Survey (NHANES) Hepatitis C Follow-Up Questionnaire was used to investigate reasons for lack of treatment and to identify strategies for improving access. Approximately 663,000 patients received antiviral therapy between 2002 and 2007, and treatment rates appear to be declining. If this trend continues, only 14.5% of liver-related deaths caused by hepatitis C from 2002-2030 will be prevented by antiviral therapy. Results from the NHANES questionnaire suggest that the primary barrier to treatment is lack of diagnosis, with 69/133 (adjusted proportion 49%) of respondents previously unaware that they had hepatitis C. CONCLUSION: Efforts to improve rates of diagnosis and treatment will be required if the future public health burden of hepatitis C is to be ameliorated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Care: Is There Enough Time for Prevention?
Yarnall, K. S. H., Pollak, K. I., Østbye, T., Krause, K. M., & Michener, J. L. (2003) · American Journal of Public Health · doi:10.2105/ajph.93.4.635 · Cited by 1,641
Cited by
Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D., Parish, B., Burke, T., Pak, W., Dunkelberg, J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009370 · Cited by 1,076
Epidemiology and natural history of HCV infection
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.107 · Cited by 994
A Primer on Effectiveness and Efficacy Trials
Singal, A. G., Higgins, P. D. R., & Waljee, A. K. (2014) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2013.13 · Cited by 698
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
El-Serag, H. B., & Kanwal, F. (2014) · Hepatology · doi:10.1002/hep.27222 · Cited by 646
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Razavi, H., ElKhoury, A. C., Elbasha, E., Estes, C., Pasini, K., Poynard, T., & Kumar, R. (2013) · Hepatology · doi:10.1002/hep.26218 · Cited by 474
Metadata
- Authors
- Volk, M. L., Tocco, R., Saini, S., & Lok, A. S. F.
- Venue
- Hepatology
- Published
- 2009-12
- Volume
- 50
- Issue
- 6
- Pages
- 1750-1755
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2021736493
- Cited by
- 224
- References
- 1
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Public health impact of antiviral therapy for hepatitis C in the United States†. https://app.cochat.ai/papers/10.1002/hep.23220
- The paper
- Volk, M. L., Tocco, R., Saini, S., & Lok, A. S. F. (2009). Public health impact of antiviral therapy for hepatitis C in the United States†. Hepatology. https://doi.org/10.1002/hep.23220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.